Genus PLC
LSE:GNS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 630
2 354
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genus PLC
Genus PLC
Additional Paid In Capital
Genus PLC
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Additional Paid In Capital
£179.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Additional Paid In Capital
$987.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Additional Paid In Capital
£364.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Additional Paid In Capital
$1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Additional Paid In Capital
$1.5B
|
CAGR 3-Years
58%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Additional Paid In Capital
£1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Genus PLC
Glance View
Genus Plc engages in the provision of genetic livestock services to produce meat and milk. The company is headquartered in Basingstoke, Hampshire and currently employs 3,096 full-time employees. The company went IPO on 2000-07-06. The firm provides farmers with genetics that enable them to produce animal protein for breeding pigs and cattle, in the form of meat and milk. The Company’s operating segments includes Genus PIC, Genus ABS and Research and Development. The Genus PIC segment is engaged in porcine sales business. The Genus ABS segment is engaged in bovine sales business. The firm's development activities include developing and maintaining its porcine genetic nucleus herd and bovine pre-stud herds. The firm operates approximately around 25 countries on six continents, with research laboratories located in Madison, Wisconsin, United States.
See Also
What is Genus PLC's Additional Paid In Capital?
Additional Paid In Capital
179.1m
GBP
Based on the financial report for Jun 30, 2024, Genus PLC's Additional Paid In Capital amounts to 179.1m GBP.
What is Genus PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
5%
Over the last year, the Additional Paid In Capital growth was 0%.
You don't have any saved screeners yet
